Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
Paolo Strati(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Simrit Parmar(The University of Texas MD Anderson Cancer Center), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Misha Hawkins(The University of Texas MD Anderson Cancer Center), Sherry Adkins(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Ryan Sun(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Michael R. Green(Harvard University), Lei Feng(Ministry of Public Security of the People's Republic of China), Swapna Johncy, Fateeha Furqan, Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Nicole Johnson, Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Haleigh Mistry, Catherine M. Claussen, Michael Wang(St. Joseph Health System), Prachee Singh, Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Chelsea C. Pinnix(The University of Texas MD Anderson Cancer Center), Sandra B. Horowitz, Raphaël Steiner(The University of Texas MD Anderson Cancer Center)
Cited by 213
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782